Inventiva (IVEVF) Net Income towards Common Stockholders (2019 - 2021)
Inventiva (IVEVF) posted Net Income towards Common Stockholders of -$11.9 million for Q2 2021, down 167.99% on a QoQ basis from -$4.4 million in Q1 2021, and down 22.57% year-over-year from -$15.4 million in Q2 2020.
Analysis
Inventiva (IVEVF) Net Income towards Common Stockholders (2019 - 2021) Analysis & Trends
Inventiva has reported Net Income towards Common Stockholders for 3 years, with the latest figure at -$11.9 million in Q2 2021.
- On a quarterly basis, Net Income towards Common Stockholders fell 22.57% year-over-year to -$11.9 million in Q2 2021; TTM through Jun 2021 was -$66.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $93.2 million, up 1703.95% from the prior year.
- Net Income towards Common Stockholders was -$11.9 million for Q2 2021 at Inventiva, down from -$4.4 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$4.4 million in Q1 2021, with the low at -$40.1 million in Q4 2020.
- Average Net Income towards Common Stockholders over 3 years is -$17.8 million, with a median of -$10.8 million recorded in 2020.
- The largest YoY upside for Net Income towards Common Stockholders was 40.67% in 2021 against a maximum downside of 22.57% in 2021.
- Over 3 years, Net Income towards Common Stockholders stood at -$33.4 million in 2019, then slipped by 20.07% to -$40.1 million in 2020, then jumped by 70.36% to -$11.9 million in 2021.
- The last three Net Income towards Common Stockholders figures came in at -$11.9 million (Q2 2021), -$4.4 million (Q1 2021), and -$40.1 million (Q4 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -238.00 Mn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 398.69 Mn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -644.37 Mn |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 333.00 Mn |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -11.89 Mn |
| Mar 31, 2021 | -4.44 Mn |
| Dec 31, 2020 | -40.11 Mn |
| Jun 30, 2020 | -9.70 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -33.40 Mn |